Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 726 results for innovative

  1. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  2. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

  3. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  4. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  5. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment (TA1063)

    Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.

  6. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  7. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

  8. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

  9. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

  10. gammaCore for cluster headache (HTG533)

    Evidence-based recommendations on gammaCore for cluster headache.

  11. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  12. ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (HTG602)

    Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.

  13. Danis stent for acute oesophageal variceal bleeding (HTG574)

    Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.

  14. Community engagement: improving health and wellbeing and reducing health inequalities (NG44)

    This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

  15. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .